Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc., commonly referred to as Intercept, is a leading biopharmaceutical company headquartered in the United States. Founded in 2002, the company has established itself in the liver disease sector, focusing on innovative therapies for chronic liver conditions. With a strong presence in North America and Europe, Intercept is dedicated to addressing unmet medical needs in hepatology. The company’s flagship product, Ocaliva (obeticholic acid), is a groundbreaking treatment for primary biliary cholangitis, setting a new standard in patient care. Intercept's commitment to research and development has positioned it as a key player in the industry, with a robust pipeline aimed at advancing liver disease treatment. Notable achievements include significant clinical trial successes and a growing reputation for excellence in the biopharmaceutical landscape.
DitchCarbon Score
How does Intercept Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Intercept Pharmaceuticals's score of 3 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Intercept Pharmaceuticals's reported carbon emissions
Intercept Pharmaceuticals, headquartered in the US, currently does not provide specific carbon emissions data or reduction targets. Without available figures on their emissions, it is unclear how they are addressing their carbon footprint or what commitments they have made towards climate action. In the absence of detailed information, it is essential to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and reducing their environmental impact. However, without specific data or commitments from Intercept Pharmaceuticals, their current stance on climate initiatives remains vague.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Intercept Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
